Data Foundry

Drug recalls 2024

EYLEA — Class II drug recall D-0531-2024

Terminated recall by Regeneron Pharmaceuticals Inc, reported 2024-06-05, distributed nationwide. Lack of Assurance of Sterility: Complaints of syringe breakage

Recall numberD-0531-2024
Product typeDrug
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmRegeneron Pharmaceuticals Inc, Tarrytown, NY, United States
Recall initiated2024-05-15
Classified2024-05-30
Reported by FDA2024-06-05
Terminated2025-09-25
DistributedNationwide (US)
Quantity405,725 prefilled
Reason classessterility, device malfunction
NDC61755-0005, 61755-0005-01, 61755-0005-02, 61755-0005-54, 61755-0005-55
Lot numbers61755-005-54, 8231500321, 8231500333, 8231500334, 8231500335, 8231500336, 8231500337, 8231500339, 8231500340, 8231500347, 8268700014, JAN-25, OCT-24

Product

EYLEA, (aflibercept) Injection, For Intravitreal injection, 2 mg (0.05mL of a 40mg/mL solution), Single-dose Pre-filled Glass Syringe, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, NDC 61755-005-01, NDC (sample lot) 61755-005-54

Reason for recall

Lack of Assurance of Sterility: Complaints of syringe breakage

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0531-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.